"Quinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D011804
|
MeSH Number(s) |
D03.633.100.810
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolines".
Below are MeSH descriptors whose meaning is more specific than "Quinolines".
This graph shows the total number of publications written about "Quinolines" by people in this website by year, and whether "Quinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1996 | 1 | 0 | 1 |
1999 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 3 | 0 | 3 |
2003 | 1 | 1 | 2 |
2004 | 0 | 2 | 2 |
2005 | 3 | 2 | 5 |
2006 | 3 | 1 | 4 |
2007 | 3 | 3 | 6 |
2008 | 0 | 3 | 3 |
2009 | 8 | 1 | 9 |
2010 | 4 | 2 | 6 |
2011 | 3 | 9 | 12 |
2012 | 8 | 6 | 14 |
2013 | 2 | 6 | 8 |
2014 | 5 | 6 | 11 |
2015 | 11 | 4 | 15 |
2016 | 8 | 6 | 14 |
2017 | 15 | 4 | 19 |
2018 | 9 | 4 | 13 |
2019 | 6 | 5 | 11 |
2020 | 5 | 3 | 8 |
2021 | 11 | 12 | 23 |
2022 | 3 | 3 | 6 |
2023 | 4 | 0 | 4 |
2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolines" by people in Profiles.
-
Thyroid Cancer: A Review. JAMA. 2024 02 06; 331(5):425-435.
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
-
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. J Immunother Cancer. 2024 01 19; 12(1).
-
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2024 Mar 01; 42(7):821-831.
-
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. Eur Urol. 2024 Mar; 85(3):229-238.
-
Nonclassical mechanisms to irreversibly suppress ?-hematin crystal growth. Commun Biol. 2023 07 27; 6(1):783.
-
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun. 2023 02 06; 14(1):630.
-
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Res. 2022 08 16; 82(16):2928-2939.
-
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. Cancer Sci. 2022 Oct; 113(10):3489-3497.
-
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 07; 36(7):1825-1833.